IMARADENANT

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H11ClFN5
Molecular Weight	315.733
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(=CC(Cl)=N1)C2=C(N=C(N)N=N2)C3=CC=C(F)C=C3

InChI

InChIKey=NCWQLHHDGDXIJN-UHFFFAOYSA-N

InChI=1S/C15H11ClFN5/c1-8-6-10(7-12(16)19-8)14-13(20-15(18)22-21-14)9-2-4-11(17)5-3-9/h2-7H,1H3,(H2,18,20,22)

HIDE SMILES / InChI

Molecular Formula	C15H11ClFN5
Molecular Weight	315.733
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Adenosine receptor A2a 15 Target ID: P29274 Gene ID: 135.0 Gene Symbol: ADORA2A Target Organism: Homo sapiens (Human) Sources: https://cancerres.aacrjournals.org/content/77/13_Supplement/5580	Antagonist 2849		1.7 nM [Ki]

C_max

Value	Dose	Analyte	Population
656 ng/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
653.8 ng/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
428.83 ng/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1054.43 ng/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
942.57 ng/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
373.8 ng/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
703.17 ng/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
538.2 ng/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1508 ng/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1107.43 ng/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
4062.5 ng × h/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4292.84 ng × h/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3328.33 ng × h/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9292.86 ng × h/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7168.57 ng × h/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1987.55 ng × h/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4848.11 ng × h/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5674 ng × h/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
21596.67 ng × h/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9967.14 ng × h/mL CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
16.02 h CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.8 h CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.05 h CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.58 h CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.19 h CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.8 h CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.28 h CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.21 h CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.97 h CLINICAL TRIAL https://aacrjournals.org/clincancerres/article/28/22/4871/710472/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635	200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	IMARADENANT plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:05:01 GMT 2025` Edited by `admin` on `Mon Mar 31 22:05:01 GMT 2025`
Record UNII	770140J08A
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZD-4635

Preferred Name

English

IMARADENANT

Official Name

English

HTL1071

Code

English

Imaradenant [WHO-DD]

Common Name

English

6-(2-CHLORO-6-METHYLPYRIDIN-4-YL)-5-(4-FLUOROPHENYL)-1,2,4-TRIAZIN-3-AMINE

Systematic Name

English

imaradenant [INN]

Common Name

English

HTL-1071

Code

English

1,2,4-TRIAZIN-3-AMINE, 6-(2-CHLORO-6-METHYL-4-PYRIDINYL)-5-(4-FLUOROPHENYL)-

Systematic Name

English

AZD4635

Code

English

Code System Code Type Description

INN

11244